Losartan in Hispanic and Latino Patients: Documented Efficacy Gaps and What the Evidence Shows

Why Ethnicity Matters for Losartan Response

Losartan is a prodrug. It does almost nothing at the angiotensin II type 1 (AT1) receptor without first being converted to E-3174 in the liver. That single biochemical fact makes every variable affecting CYP2C9 activity clinically relevant, and CYP2C9 activity varies substantially across ancestral populations. Hispanic and Latino patients represent a genetically heterogeneous group descended from Indigenous American, European, and West African ancestries in varying proportions. That admixture creates a pharmacogenomic profile that does not map neatly onto the "Hispanic" checkbox in most clinical trials, which is partly why the evidence base contains real gaps.

The Prodrug Bioactivation Problem

After oral dosing, approximately 14% of losartan is converted to E-3174 by CYP2C9 and, to a lesser degree, CYP3A4 [1]. E-3174 is 10 to 40 times more potent at the AT1 receptor than the parent compound. In patients carrying two loss-of-function CYP2C9 alleles (poor metabolizers), E-3174 area under the curve (AUC) drops by roughly 50% compared with extensive metabolizers, measurably blunting the antihypertensive effect [2].

Plasma Renin and the Angiotensin Axis

ARBs work by blocking angiotensin II at the AT1 receptor, so patients with low baseline renin activity get less from the drug. Some epidemiological studies have documented lower average plasma renin activity in Black patients, which is part of why ACE inhibitors and ARBs as monotherapy historically underperform in that population. Hispanic and Latino patients occupy a middle position. Data from NHANES-linked cohorts suggest plasma renin activity in Mexican-American adults is modestly lower than in non-Hispanic White adults [3]. The clinical consequence is a ceiling on blood-pressure response that is independent of pharmacogenomics.

CYP2C9 Variant Allele Frequencies in Hispanic and Latino Populations

The two most clinically significant loss-of-function variants are CYP2C92 (p.Arg144Cys) and CYP2C93 (p.Ile359Leu). Both reduce enzyme activity. CYP2C93 is more severe, producing roughly 5% of normal metabolic capacity compared with about 30% for CYP2C92 [4].

Allele Frequencies by Subgroup

Because "Hispanic" encompasses Mexican, Puerto Rican, Cuban, Central American, and South American ancestries, allele frequencies are not uniform. PharmGKB (Level 1A evidence for the CYP2C9-losartan interaction) aggregates population data showing [5]:

• CYP2C9*2: approximately 8-14% allele frequency across studied Hispanic cohorts.
• CYP2C9*3: approximately 2-6%, with Puerto Rican-ancestry individuals trending toward the higher end of that range in some datasets.

For comparison, CYP2C92 frequency in non-Hispanic White populations runs around 12-13%, and CYP2C93 around 6-7%. The differences are modest at the population level, but the combination of intermediate and poor metabolizer phenotypes reaches roughly 30-40% of the Hispanic population in aggregate, meaning a substantial fraction of patients may have meaningfully reduced E-3174 exposure at standard losartan doses.

What Poor Metabolizer Status Means Clinically

A patient who is a CYP2C9 poor metabolizer prescribed losartan 50 mg once daily may be receiving the pharmacological equivalent of a much lower effective dose. The parent compound accumulates, E-3174 does not, and the net AT1-receptor blockade is attenuated. In one pharmacokinetic crossover study, CYP2C9*3/*3 subjects showed an E-3174 AUC that was 55% lower than wild-type subjects at the same losartan dose [2]. Blood pressure response tracked accordingly.

The HealthRX clinical team uses a three-step assessment protocol for Hispanic and Latino patients starting losartan:

1. Verify baseline blood pressure, kidney function (eGFR), and potassium before initiation.
2. Assess clinical risk factors for CYP2C9 reduced function (co-medications, prior poor ARB response, family history of unusual drug metabolism) and consider pharmacogenomic testing if two or more risk factors are present.
3. Reassess blood-pressure control at four weeks. If systolic BP remains above 130 mmHg on losartan 50 mg, titrate to 100 mg before switching drug class.

Evidence from Clinical Trials: What the LIFE Trial and Other Data Show

The LIFE Trial and Its Hispanic Subgroup Limitations

The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial, published in The Lancet in 2002, enrolled 9,193 patients with hypertension and left ventricular hypertrophy and compared losartan-based versus atenolol-based therapy over a mean 4.8 years [6]. The primary composite endpoint (cardiovascular death, stroke, myocardial infarction) was reduced by 13% in the losartan arm (hazard ratio 0.87, 95% CI 0.77-0.98, P=0.021).

LIFE enrolled patients from Scandinavia, the United Kingdom, and the United States. The U.S. Cohort included Hispanic patients, but the trial pre-specified ethnicity-stratified analyses only for Black patients, in whom losartan performed no better than atenolol on the primary endpoint. Published subgroup tables do not provide a Hispanic-specific hazard ratio, leaving a documented evidence gap that has not been filled by a dedicated Hispanic-enriched ARB trial [6].

The RENAAL Trial and Diabetic Nephropathy

The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial enrolled 1,513 patients with type 2 diabetes and nephropathy and showed that losartan 50-100 mg daily reduced the risk of doubling serum creatinine, end-stage renal disease (ESRD), or death by 16% versus placebo (P=0.02) [7]. The trial enrolled patients from Latin America as well as North America, Europe, Asia-Pacific, and South Africa. Post-hoc analyses reported regional effects, but "Latin American" as a regional category mixes national-origin groups and does not resolve the pharmacogenomic question.

The RENAAL investigators noted that baseline HbA1c averaged 8.5% and that Hispanic patients in the U.S. Subgroup of the broader literature tend to have higher HbA1c at enrollment, meaning they may carry more renal risk at the same drug exposure level [7]. Renoprotective ARB dosing depends in part on how much AT1-receptor blockade is achieved, which circles back to CYP2C9 metabolizer status.

Smaller Pharmacokinetic Studies Filling the Gap

A dedicated pharmacokinetic study by Yasar et al. In Clinical Pharmacology and Therapeutics characterized losartan metabolism across CYP2C9 genotype groups and provided the foundational AUC data showing the 50% reduction in E-3174 in poor metabolizers [2]. The study did not enroll Hispanic patients as a distinct category, but because CYP2C9*2 and *3 are the relevant alleles in both Hispanic and non-Hispanic populations, the metabolic consequence of a given genotype is the same regardless of ethnicity. The ethnicity-specific question is frequency, not magnitude of effect.

Diabetes Prevalence, Insulin Resistance, and the Stakes of Adequate BP Control

A Higher-Risk Starting Point

Among U.S. Hispanic and Latino adults, the age-adjusted prevalence of diagnosed diabetes is 11.8%, compared with 7.4% in non-Hispanic White adults (CDC National Diabetes Statistics Report, 2022) [8]. Type 2 diabetes is the leading cause of chronic kidney disease and a major driver of cardiovascular events, which are the same outcomes that losartan is prescribed to prevent or delay. Any pharmacogenomic or pharmacodynamic factor that attenuates losartan efficacy in this population therefore has disproportionately large consequences.

Blood Pressure Targets in Diabetic Kidney Disease

The American Diabetes Association (ADA) Standards of Care 2024 recommend a blood pressure target of <130/80 mmHg for adults with diabetes and hypertension, with an ACE inhibitor or ARB as preferred agents in those with albuminuria [9]. The ADA guideline states directly: "In patients with type 2 diabetes, hypertension, and albuminuria, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are recommended to slow the progression of chronic kidney disease." Reaching that <130/80 mmHg target in a CYP2C9 intermediate or poor metabolizer on standard-dose losartan is harder, not impossible, but it requires attentive dose titration.

Albuminuria and Renin Activity in Hispanic Cohorts

Hispanic adults with type 2 diabetes show higher rates of microalbuminuria compared with non-Hispanic White adults in cross-sectional data from the Multi-Ethnic Study of Atherosclerosis (MESA), suggesting a higher baseline renal risk burden [10]. If renin activity is simultaneously lower, the double challenge is that the kidneys are more vulnerable and the drug that targets the renin-angiotensin axis may work less efficiently. This is not a reason to avoid ARBs. It is a reason to optimize the dose.

Pharmacogenomic Testing: Practical Guidance for Clinicians

When to Order a CYP2C9 Genotype

Routine pharmacogenomic testing before starting an ARB is not yet standard of care and is not recommended in current ADA or JNC guidelines. Testing becomes worth discussing in three specific situations:

• A patient with hypertension and at least moderate albuminuria who shows <5 mmHg systolic reduction after four to six weeks on losartan 100 mg daily.
• A patient who has tried two ARBs at maximum doses without achieving target BP and who has no identifiable secondary cause.
• A patient already enrolled in a pharmacogenomics program at their institution (increasingly common at academic medical centers).

Interpreting Results

PharmGKB assigns CYP2C9-losartan a Level 1A evidence rating, meaning the association between genotype and drug response is supported by multiple replicated studies and is considered actionable [5]. The Clinical Pharmacogenomics Implementation Consortium (CPIC) has not yet published a dosing guideline specific to losartan, but the CPIC warfarin guideline (which covers CYP2C9 phenotype-based dosing) provides the validated phenotype definitions used across drug classes. A patient with CYP2C9*1/*3 is an intermediate metabolizer; *3/*3 is a poor metabolizer; *1/*1 is an extensive metabolizer.

Alternative Agents in Poor Metabolizers

Irbesartan and candesartan do not require CYP2C9 bioactivation. Irbesartan is itself the active compound; candesartan cilexetil is converted to candesartan by ester hydrolysis rather than hepatic CYP metabolism. For a confirmed CYP2C9 poor metabolizer who needs AT1-receptor blockade, switching to irbesartan 150-300 mg daily or candesartan 8-32 mg daily avoids the bioactivation bottleneck entirely. The IDNT trial (N=1,715) demonstrated irbesartan's renoprotective effect in type 2 diabetic nephropathy independently of blood-pressure lowering, providing a solid evidence base for that switch [11].

Dosing Considerations Specific to Hispanic and Latino Patients

Starting Dose and Titration Schedule

The FDA-approved dosing range for losartan in hypertension is 25-100 mg daily as a single dose or split into two doses. For diabetic nephropathy, the RENAAL protocol started at 50 mg and titrated to 100 mg at four weeks if tolerated [7]. In Hispanic and Latino patients, the HealthRX clinical team recommends:

• Start at 50 mg once daily.
• Reassess blood pressure and potassium at four weeks.
• Titrate to 100 mg if systolic BP remains above target.
• At eight weeks on 100 mg, if systolic BP remains above 130 mmHg, add amlodipine 5 mg before switching ARB class. Combination ARB-plus-CCB therapy is guideline-supported and addresses both the renin-mediated and non-renin-mediated components of blood pressure.

Concomitant Medications That Inhibit CYP2C9

Several drugs commonly prescribed to Hispanic adults with diabetes and hypertension are also CYP2C9 inhibitors, which paradoxically increase E-3174 exposure by slowing losartan metabolism. Fluconazole (used frequently in patients with recurrent vaginal candidiasis, which is more common in poorly controlled diabetes) is a potent CYP2C9 inhibitor. Amiodarone and fluoxetine carry moderate inhibitory activity. A patient on fluconazole plus losartan 100 mg may see supra-therapeutic AT1 blockade and hypotension. Review the medication list at every visit.

Sodium Intake and Dietary Context

Higher dietary sodium blunts the antihypertensive effect of ARBs by suppressing renin and shifting blood pressure regulation toward volume-dependent mechanisms. Traditional dietary patterns in several Latin American communities include high sodium content from processed foods, canned goods, and restaurant eating. The DASH-sodium trial showed that reducing sodium intake from 150 to 50 mmol/day lowered systolic BP by an additional 6.7 mmHg in hypertensive adults [12]. Dietary counseling is not a substitute for dose optimization, but it is an evidence-based complement that matters more in a population where renin activity may already be at the lower end.

What Clinicians Should Document and Monitor

Regardless of pharmacogenomic status, every Hispanic or Latino patient on losartan needs the following monitoring schedule, consistent with ADA and ACC/AHA hypertension guideline recommendations:

• Baseline: Serum creatinine, eGFR, potassium, urine albumin-to-creatinine ratio (UACR), and blood pressure in both arms.
• At 2-4 weeks after initiation or dose change: Potassium and creatinine (a rise of <30% in creatinine is acceptable and does not require discontinuation).
• Every 3-6 months: Blood pressure, UACR, and potassium in patients with CKD or diabetes.
• Annually: eGFR and a review of concomitant nephrotoxic or CYP2C9-interacting medications.

A UACR that is not declining by at least 30% after six months on maximum-tolerated losartan dose is a signal to reassess adherence, dietary sodium, and whether a pharmacogenomic barrier to bioactivation may be present.